Dayvigo (Lemborexant) for Insomnia: Risks and Benefits
Dayvigo (lemborexant) is an effective treatment for insomnia that significantly improves sleep maintenance with a favorable safety profile, though somnolence is the primary adverse effect requiring monitoring.
Benefits
Sleep Efficacy
Lemborexant demonstrates robust improvements across multiple sleep parameters:
- Wake After Sleep Onset (WASO): Reduces nighttime awakenings by approximately 20-22 minutes compared to placebo 1, 2
- Sleep Efficiency: Improves by 4.8-7.5% depending on dose (5mg vs 10mg) 1, 2
- Sleep Onset Latency: Decreases time to fall asleep by 9-13 minutes 1, 2
- Total Sleep Time: Increases by approximately 16 minutes 3
The 2025 meta-analyses provide the strongest recent evidence, showing lemborexant ranks among the highest-performing hypnotics in network comparisons 4. Importantly, these benefits persist long-term, with objective sleep EEG monitoring demonstrating sustained improvements at both 4 and 12 weeks 5.
Unique Advantages
Unlike traditional benzodiazepines and Z-drugs, lemborexant:
- Shows minimal next-morning cognitive impairment or residual sedation 4, 6
- Demonstrates no significant withdrawal symptoms or dependence 4
- Improves daytime functioning and depressive symptoms 5
- Safe in patients with mild obstructive sleep apnea and COPD 4, 6
Risks
Common Adverse Effects
Somnolence is the primary concern, occurring in approximately 7% of patients on 15-20mg doses versus 3% with placebo 3. The FDA label warns specifically about 7:
- Decreased awareness and alertness the morning after use
- Increased fall risk, particularly in elderly patients
- Daytime impairment if taken with less than 7 hours of sleep remaining
Serious but Rare Adverse Effects
The FDA labeling identifies several important warnings 7:
- Complex sleep behaviors: Sleep-walking, sleep-driving, eating while not fully awake (requires immediate discontinuation)
- Sleep paralysis and hallucinations: Hypnagogic/hypnopompic hallucinations and cataplexy-like symptoms
- Worsening depression/suicidal ideation: Particularly in patients with pre-existing depression
- Cognitive and behavioral changes: Amnesia, anxiety, hallucinations
Treatment-Related Adverse Events
Meta-analysis shows lemborexant carries 1.82 times higher risk of treatment-related adverse events compared to placebo 1, though overall adverse event rates are not significantly different. Importantly, serious adverse events remain negligible and comparable to placebo 3.
Clinical Considerations
Dosing Strategy
- Start with 5mg in most patients, particularly those ≥65 years old 7
- 10mg dose shows marginally better efficacy but higher somnolence rates (9.8% vs 4.9% in elderly) 7
- Take only when able to remain in bed for ≥7 hours 7
- Avoid taking with or soon after meals (delays absorption) 7
Contraindications and Precautions
Do not use in patients with narcolepsy 7
Exercise caution in:
- Elderly patients (higher fall risk due to somnolence) 7
- Moderate hepatic impairment (requires dose reduction to 5mg maximum) 7
- Severe hepatic impairment (not recommended) 7
- Severe renal impairment (increased exposure but no dose adjustment required) 7
Drug Interactions
Avoid alcohol completely when taking lemborexant 7. Use caution with other CNS depressants unless specifically directed by a physician.
Comparative Context
While older guidelines from 2016-2017 discuss suvorexant (another orexin antagonist) 8, 3, lemborexant represents a newer agent with superior pharmacokinetic properties 4, 9. The 2025 evidence demonstrates lemborexant's relative selectivity for orexin receptor type 2, providing quick onset with steep plasma decline that minimizes morning residual effects despite a long terminal half-life 4.
The key advantage over traditional hypnotics: Lemborexant avoids the tolerance, dependence, cognitive impairment, and fall risks associated with benzodiazepines and Z-drugs 4, 9, making it particularly valuable for long-term management and in elderly populations where these risks are most concerning.